DeepX Health, a teledermatology and AI diagnostic company specializing in the early detection of skin cancer, proudly announces the appointment of Andre Esteva as its newest advisory board member.
“DeepX’s approach to commercializing AI-based skin diagnostics is unique,” said Andre Esteva. “Their substantial international market traction indicates an insightful way to penetrate this very large and very complex space. It’s noteworthy to see the substantial progress achieved through revenue, rather than solely relying on investment capital.”
With a distinguished background in pioneering medical AI solutions, Esteva brings a wealth of experience from his tenure as Head of Medical AI at Salesforce Research and various roles at esteemed institutions including Google Research, Sandia National Labs, and GE Healthcare. He currently serves as the Founder and CEO of Artera AI, a pioneer in medical AI.
Esteva’s illustrious career has been marked by his groundbreaking research focusing on medical AI diagnostics and precision medicine. Notably, he was the co-lead author of one of the seminal papers on deep learning algorithms for skin cancer detection published in Nature in 2017. His publications have been on the covers of prestigious journals such as Nature and Nature Medicine, and have been featured in other top journals including Cell, The Lancet, and NeurIPS. His work has received widespread attention from media outlets such as The Wall Street Journal, Fortune, BBC, and The Economist, solidifying his reputation as a thought leader in the field.
A Stanford alumn, Esteva earned his PhD in Artificial Intelligence, specializing in deep learning and computer vision applied to healthcare. Prior to this, he achieved undergraduate degrees with highest honors in Electrical Engineering and Pure Mathematics from UT-Austin, where he was honored as Engineering Valedictorian.
On the Board of Advisors of DeepX Health, Esteva will contribute to the company’s mission to revolutionize skin healthcare through cutting-edge AI technologies, building upon his proven track record of innovation and leadership in the industry.
Christian Horn, founder and CEO of DeepX Health, said, “We are thrilled to welcome Andre Esteva to DeepX Health’s advisory board. His extensive experience and groundbreaking contributions to AI diagnostics will be invaluable as we continue to innovate and expand our teledermatology and diagnostic solutions.”
About Skin Cancer
Skin cancer is the most prevalent cancer worldwide. In the United States alone, it is estimated that about 5 million adults are treated for skin cancer each year. Approximately 1/5 people in the US will develop skin cancer in their lifetime, and nearly 20 Americans die from melanoma each day. The most prevalent types of skin cancer are melanoma, basal cell carcinoma and squamous cell carcinoma. Early detection is critical to improve the survivability of skin cancer.
About DeepX Health
DeepX Health is a teledermatology and skin cancer diagnostics company working to enable early skin cancer diagnosis by integrating device technology, AI, and teledermatology. Our DermoSight dermatoscope is designed for integration with our AI diagnostics algorithm (in development), empowered by our proprietary “Optical Biopsy” technology.
Our DermoSight service has facilitated over 200,000 consultations in Boots pharmacies and primary care locations across Europe. DermoSight is FDA cleared and ready for U.S market entry, demonstrating our commitment to advancing teledermatology for the benefits of patients and practitioners everywhere.
For more information, please visit www.deepxhealth.com
For all enquiries, please contact info@deepxhealth.com